Phreesia Turns Profit, Boosts Cash Flow Amid Revenue Outlook Cut
Event summary
- Phreesia achieved positive GAAP net income of $2.3 million and generated $78.8 million in net cash from operating activities in fiscal year 2026.
- The company's revenue increased 16% year-over-year to $127.1 million in the fourth quarter and 14% to $480.6 million for the full fiscal year.
- Phreesia completed the acquisition of AccessOne for approximately $164 million, funded through a bridge loan and subsequent refinancing.
- The company is lowering its revenue outlook for fiscal 2027, citing reduced spending commitments from pharmaceutical manufacturers.
The big picture
Phreesia's turnaround, marked by profitability and strong cash flow generation, is now facing headwinds from macroeconomic uncertainty and shifting industry dynamics. The AccessOne acquisition aimed to expand the company's payment solutions offerings, but the subsequent revenue outlook cut suggests integration challenges or broader market pressures. The company's reliance on pharmaceutical manufacturers for a significant portion of its revenue exposes it to regulatory and commercial risks within the healthcare sector.
What we're watching
- Revenue Visibility
- The extent to which Phreesia can regain visibility into pharmaceutical manufacturer spending will be a key determinant of future revenue performance, potentially requiring adjustments to forecasting models.
- Integration Risk
- The success of integrating AccessOne and realizing the anticipated revenue synergies will be critical to offsetting the revenue outlook reduction and justifying the acquisition cost.
- AI Efficiency
- Whether Phreesia's planned adoption of AI can deliver the promised efficiencies and offset margin pressure remains to be seen, and will be a key indicator of operational resilience.
Related topics